Keyword search (3,448 papers available)


Deprescribing: Future directions for research.

Author(s): Thompson W, Reeve E, Moriarty F, Maclure M, Turner J, Steinman MA, Conklin J, Dolovich L, McCarthy L, Farrell B

Res Social Adm Pharm. 2019 06;15(6):801-805 Authors: Thompson W, Reeve E, Moriarty F, Maclure M, Turner J, Steinman MA, Conklin J, Dolovich L, McCarthy L, Farrell B

Article GUID: 30241876
Title:Deprescribing: Future directions for research.
Authors:Thompson W,  Reeve E,  Moriarty F,  Maclure M,  Turner J,  Steinman MA,  Conklin J,  Dolovich L,  McCarthy L,  Farrell B
Link:https://www.ncbi.nlm.nih.gov/pubmed/30241876?dopt=Abstract
DOI:10.1016/j.sapharm.2018.08.013
Category:Res Social Adm Pharm
PMID:30241876
Dept Affiliation: CONCORDIA
1 Research Unit of General Practice, Department of Public Health, University of Southern Denmark, JB Winsløwsvej 9A, 5000C, Odense, Denmark. Electronic address: wthomp01@gmail.com.
2 NHMRC Cognitive Decline Partnership Centre, Kolling Institute of Medical Research, Northern Clinical School, Faculty of Medicine and Health, University of Sydney, Royal North Shore Hospital, St Leonards, NSW, 2065, Australia; Geriatric Medicine Research, Faculty of Medicine and College of Pharmacy, Dalhousie University and Nova Scotia Health Authority, NS, Canada. Electronic address: emily.reeve@sydney.edu.au.
3 HRB Centre for Primary Care Research, Royal College of Surgeons in Ireland, 123 St Stephen's Green, D02 YN77, Dublin, Ireland. Electronic address: frankmoriarty@rcsi.ie.
4 Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2775 Laurel Street, V5Z 1M9, Vancouver, British Columbia, Canada. Electronic address: malcolm.maclure@ubc.ca.
5 University of Montreal, Centre de recherche, Institut Universitaire de Gériatrie de Montréal, 4545 Chemin Queen Mary, H3W 1W4, Montréal, Quebec, Canada. Electronic address: justin.turner@criugm.qc.ca.
6 Division of Geriatrics, Department of Medicine, University of California San Francisco, 4150 Clement St., Box 181G, 94121, San Francisco, USA. Electronic address: mike.steinman@ucsf.edu.
7 Bruyère Research Institute, Ottawa, Ontario, Canada; Concordia University, Montreal, Quebec, Canada. Electronic address: james.conklin@concordia.ca.
8 Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, M5S 3M2, Toronto, Ontario, Canada; Department of Family Medicine, McMaster University, Hamilton, Ontario, Canada. Electronic address: lisa.dolovich@utoronto.ca.
9 Women's College Research Institute, Women's College Hospital, 76 Grenville St., M5S 1B2, Toronto, Ontario, Canada; Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, M5S 3M2, Toronto, Ontario, Canada; Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address: lisa.mccarthy@utoronto.ca.
10 Bruyère Research Institute, Ottawa, Ontario, Canada; Department of Family Medicine, University of Ottawa, Ottawa, Ontario, Canada; School of Pharmacy, University of Waterloo, Kitchener, Ontario, Canada. Electronic address: bfarrell@bruyere.org.

Description:

Deprescribing: Future directions for research.

Res Social Adm Pharm. 2019 06;15(6):801-805

Authors: Thompson W, Reeve E, Moriarty F, Maclure M, Turner J, Steinman MA, Conklin J, Dolovich L, McCarthy L, Farrell B

Abstract

A World Café workshop was held at the Bruyère Evidence-Based Deprescribing Guidelines Symposium in March 2018 with 30 participants (researchers, clinicians, policy makers, stakeholders). This workshop explored priorities for future work in the field of deprescribing and deprescribing guidelines through group discussion. The discussions were guided by the following questions: (1) What are deprescribing research priorities (to inform guideline development), (2) What outcome measures are important for developing deprescribing guidelines, and (3) How do we evaluate the implementation and effectiveness of deprescribing guidelines? Discussion from all 3 questions identified 6 main priority areas: (1) conducting high-quality and long-term clinical trials that measure patient-important outcomes, (2) focusing on patient involvement and perspectives, (3) investigating the pharmacoeconomics of deprescribing interventions, (4) understanding deprescribing interventions in different populations, (5) generating evidence on clinical management during deprescribing (e.g. managing adverse drug withdrawal effects, subsequent re-prescribing), and (6) implementing interventions in clinical practice. These topics represent what a group of experienced researchers, clinicians, and stakeholders in the field collectively felt was important to consider for design and implementation of future deprescribing studies. The aim is for these findings to stimulate future discussions and be considered by granting agencies, policy makers, deprescribing research networks, and individual researchers planning future deprescribing studies.

PMID: 30241876 [PubMed - indexed for MEDLINE]